These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 32923230)
1. Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge. Khan AM; Ajmal Z; Raval M; Tobin E Cureus; 2020 Aug; 12(8):e9629. PubMed ID: 32923230 [TBL] [Abstract][Full Text] [Related]
2. Acute Myeloid Leukemia with Philadelphia Chromosome, Near-tetraploidy, and 5q Deletion. Khan AM; Munir A; Asrani R; Najjar S Cureus; 2019 Sep; 11(9):e5606. PubMed ID: 31700719 [TBL] [Abstract][Full Text] [Related]
3. Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases. Vanegas YAM; Azzouqa AM; Menke DM; Foran JM; Vishnu P Hematol Rep; 2018 Sep; 10(3):7658. PubMed ID: 30283621 [TBL] [Abstract][Full Text] [Related]
4. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100 [TBL] [Abstract][Full Text] [Related]
5. Viral Clearance with Neutrophil Recovery in a Patient with Active COVID-19 Infection and Refractory Acute Myeloid Leukemia Who Underwent Successful Reinduction with Cytarabine/Idarubicin. Dean EA; Brown RA; Kaur P; Casaus DV Case Rep Oncol; 2022; 15(2):705-712. PubMed ID: 36157697 [TBL] [Abstract][Full Text] [Related]
6. Cirrhosis With Splenomegaly and Pancytopenia Complicating a Concurrent Diagnosis of Acute Lymphoblastic Leukemia. Kanakamedala S; Danak SU; Conway EJ; Kotla V Cureus; 2022 Nov; 14(11):e31707. PubMed ID: 36561590 [TBL] [Abstract][Full Text] [Related]
7. Myocarditis Concurrent with Sweet Syndrome: A Presentation of Acute Myeloid Leukemia. Burkeen CG; Pottinger D; Iragavarapu C; Ramlal R; Hildebrandt G Case Rep Hematol; 2021; 2021():6621007. PubMed ID: 34055428 [TBL] [Abstract][Full Text] [Related]
8. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report. Wang L; Lin N Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607 [TBL] [Abstract][Full Text] [Related]
9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
10. Acute panmyelosis with myelofibrosis - a rare subtype of acute myeloid leukemia. Chatterjee T; Gupta S; Sharma A; Sharma S; Gupta D Mediterr J Hematol Infect Dis; 2013; 5(1):e2013042. PubMed ID: 23795280 [TBL] [Abstract][Full Text] [Related]
11. Atypical Presentation of Acute Myeloid Leukemia. Agrawal K; Miles L; Agrawal N; Khan A World J Oncol; 2018 Feb; 9(1):29-34. PubMed ID: 29581813 [TBL] [Abstract][Full Text] [Related]
12. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609 [TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD Mutation and Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Case Study. Saeed S; Halappa Nagaraj R; Grezenko H; Rehman A; Shehryar A; Anwaar MA; Lazarevic S; Shahzed SMI; Das A; Vargas KI Cureus; 2023 Jul; 15(7):e42504. PubMed ID: 37637651 [TBL] [Abstract][Full Text] [Related]
14. New drugs creating new challenges in acute myeloid leukemia. Tiong IS; Wei AH Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214 [TBL] [Abstract][Full Text] [Related]
15. T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report. Park S; Jeong EJ; Kang JH; Lee GW; Go SI; Lee DH; Koh EH World J Clin Cases; 2023 Sep; 11(26):6200-6205. PubMed ID: 37731550 [TBL] [Abstract][Full Text] [Related]
16. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Ogasawara T; Yasuyama M; Kawauchi K Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101 [TBL] [Abstract][Full Text] [Related]
17. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia. Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023 [TBL] [Abstract][Full Text] [Related]
18. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. Kim M; Williams S Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662 [TBL] [Abstract][Full Text] [Related]
19. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
20. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia]. Kunisada K; Matsuoka A; Yoshida S; Taoka T Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]